Source:http://linkedlifedata.com/resource/pubmed/id/15118508
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2004-4-30
|
pubmed:abstractText |
Corticosteroids are traditionally used for inflammatory disorders because of their ability to diminish neutrophil transmigration, limit access to sites of inflammation, and decrease cytokine production. More recently, however, investigators have focused on the angiostatic and antipermeability properties of corticosteroids for posterior segment diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and macular edema. Both new angiostatic and traditional corticosteroids are currently undergoing evaluation as new delivery techniques such as intravitreal injection and intraocular sustained-release devices facilitate high local angiostatic and antipermeability concentrations while minimizing extraocular toxicity. The purpose of this review is to discuss recent work concerning both the mechanism and effectiveness of these newer treatments.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1040-8738
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
15
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
211-20
|
pubmed:dateRevised |
2006-10-13
|
pubmed:meshHeading | |
pubmed:year |
2004
|
pubmed:articleTitle |
Corticosteroids in posterior segment disease: an update on new delivery systems and new indications.
|
pubmed:affiliation |
Midwest Eye Institute, 201 Pennsylvania Parkway, Indianapolis, IN 46280, USA. thomasciulla@yahoo.com
|
pubmed:publicationType |
Journal Article,
Review
|